BJU Int
- TAKAHASHI T
Endpoint and control group in prostate cancer screening research: public health
basics.
BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
- ALBERTSEN PC
Response to 'Endpoint and control group in prostate cancer screening research:
public health basics'.
BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
BMC Cancer
- AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
Correction: Health-related quality of life of metastatic prostate cancer patients
treated with prostate Radiotherapy.
BMC Cancer. 2024;24:419.
BMC Urol
- WU F, Huang F, Jiang N, Su J, et al
Identification of ferroptosis related genes and pathways in prostate cancer cells
under erastin exposure.
BMC Urol. 2024;24:78.
- CHENG Y, Fan B, Fu Y, Yin H, et al
Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI:
development and internal validation of a clinical-radiological characteristics
based nomogram.
BMC Urol. 2024;24:76.
Cancer Imaging
- KOLADE OU, Brink A, Ayeni AO, More S, et al
Optimizing PSMA scintigraphy for resource limited settings - a retrospective
comparative study.
Cancer Imaging. 2024;24:46.
Eur Urol
- ROY S, Fervaha G, Spratt DE, Sun Y, et al
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer:
A Network Meta-analysis.
Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
- ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic
Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
Int J Radiat Oncol Biol Phys
- MAITRE P, Maheshwari G, Sarkar J, Singh P, et al
Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate
cancer: Dose-effect relations in the POP-RT randomized phase III trial.
Int J Radiat Oncol Biol Phys. 2024 Mar 27:S0360-3016(24)00439.
Int J Urol
- YAMAMOTO Y, Nonomura N
Editorial Comment to Survival beyond cabazitaxel for metastatic
castration-resistant prostate cancer.
Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
- URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
Prostate cancer and liquid biopsies: Clinical applications and challenges.
Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
- GOTO Y
Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications
and challenges.
Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
J Nucl Med
- SHI J, Li D, Chen M, Fu Y, et al
The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions
on Multiparametric MRI: A Prospective Single-Center Study.
J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
- HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and
Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
J Nucl Med. 2024;65:566-572.
- LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor
Quantification and Prognosis of Cancer on PET/CT.
J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
Oncogene
- CHEN M, Zou C, Tian Y, Li W, et al
An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a
tumor suppressive role in aggressive prostate cancer.
Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
Oncol Rep
- HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
Butyrate increases methylglyoxal production through regulation of the
JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
Oncol Rep. 2024;51:71.
PLoS One
- FONSECA-ALVES CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, et al
Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis
in human and canine prostate cancer cells.
PLoS One. 2024;19:e0297043.
Proc Natl Acad Sci U S A
- HE T, Cheng C, Qiao Y, Cho H, et al
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired
mechanisms of resistance in prostate cancer.
Proc Natl Acad Sci U S A. 2024;121:e2322563121.
Prostate
- GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
Natural course of metastatic castration-resistant prostate cancer in the era of
intensified androgen deprivation therapy in the hormone-sensitive setting.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
- KIM J, Park S, Kim S, Ryu S, et al
Enhancing the anticancer effect of androgen deprivation therapy by
monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
- KU HC, Cheng E, Cheng CF
A body shape index (ABSI) but not body mass index (BMI) is associated with
prostate cancer-specific mortality: Evidence from the US NHANES database.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
- MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in
whole blood.
Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
- MARTELIN N, De Witt B, Chen B, Eschwege P, et al
Development and validation of an imageless machine-learning algorithm for the
initial screening of prostate cancer.
Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
Radiology
- JEWELL K, Hofman MS, Ong JSL, Levy S, et al
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific
Membrane Antigen Therapy.
Radiology. 2024;311:e231703.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016